461 Angiotensine-receptors blockers but not angiotensin-converting enzime inhibitors delay the progression of aortic stenosis

Abstract

Background was signicantly (p=0.01) lower in patients with ARBs (0.12 ±0.20 m.s -1 .y -1 ) compared to those with no RAS medication (0.21 ±0.22 m.s -1 .y -1 ). After adjustment for propensity score, ARBs was signicantly (p=0.001) associated with slower� AS progression, compared to other groups. On multivariable regression model including age, male gender, diabetes, baseline peak aortic jet velocity, valvulo-arterial impedance and propensity score, treatment with ARBs (p=0.005) but notwith ACEIs (p=0.72), was an independent predictor of lower AS progression. Conclusion: This study suggests that ARBs but not ACEIs delayAS progression. These results could be explained by the fact that ARBs provide more complete blockade ofinammatory andbro-calcic processes contributing toAS progression. Thesendings open new avenues for the pharmacological treatment of AS and provide impetus for the elaboration of randomized studies focusing on ARBs in this population.